ATx201

Phase I study – 36 Healthy volunteers:

  • Place: Department of Clinical Pharmacology, Medical University of Vienna
  • PI: Dr. Markus Zeitlinger
  • Prospective, randomized, double-blind, placebo controlled study
  • 36 healthy volunteers
  • Split body design
  • 7-day treatment, maximal dose
  • Safety of formulation (Systemic exposure: Blood PK, biomarkers and irritation)

 

For more information about this study please visit clinicaltrialsregister.eu and clinicaltrials.gov

 

Learn more